Marker Therapeutics

Marker Therapeutics:
Focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. MT-401, its lead MultiTAA-specific T cell product candidate, has received Orphan Drug Designation for the treatment of post-transplant acute myeloid leukemia (AML) and is currently in a Ph 2 study (n=160) evaluating clinical efficacy in both the adjuvant (n=120) and active disease (n=40) setting. Topline results from the active disease group is expected in Q1 2022.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology
Industry
Biotechnology, Pharmaceuticals
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
3200 Southwest Fwy #2240, Phoenix Tower
Houston, TX 77027
United States
Houston, TX 77027
United States
More info:
My account:
Company Participants at Solebury Trout Hamptons CEO Roundtable 2021
- Peter L. Hoang, President & CEO
Top 10 Holders of Marker Therapeutics, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
NEA Management Co. | 12.90 | 10,714,285 | 5.79 | 13F | 3/31/22 |
Aisling Capital Management LP | 3.78 | 3,142,857 | 1.70 | 13F | 3/31/22 |
Long Focus Capital Management LLC | 2.93 | 2,435,863 | 1.32 | 13F | 3/31/22 |
Wellington Management Co. LLP | 2.86 | 2,378,629 | 1.28 | Funds | 9/30/21 |
The Vanguard Group, Inc. | 2.78 | 2,319,835 | 1.25 | Funds | 6/30/22 |
Vanguard Group, Inc. (Subfiler) | 2.75 | 2,282,168 | 1.23 | 13F | 3/31/22 |
Renaissance Technologies LLC | 0.70 | 584,272 | 0.32 | 13F | 3/31/22 |
Geode Capital Management LLC | 0.70 | 579,099 | 0.31 | 13F | 3/31/22 |
Norges Bank Investment Management | 0.53 | 443,493 | 0.24 | Funds | 12/31/21 |
ACT Capital Management LLC | 0.43 | 354,400 | 0.19 | 13F | 3/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.